8-(2-hydroxy-2-ethoxyacetyl)-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one | 124955-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 8-(2-hydroxy-2-ethoxyacetyl)-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one
• 英文别名: 6-benzyloxy-8-(2-ethoxy-2-hydroxy-acetyl)-4H-benzo[1,4]oxazin-3-one；6-benzyloxy-8-(2-ethoxy-2-hydroxyacetyl)-4H-benzo[1,4]oxazin-3-one；8-(2-ethoxy-2-hydroxyacetyl)-6-phenylmethoxy-4H-1,4-benzoxazin-3-one
• CAS: 124955-27-7
• 化学式: C₁₉H₁₉NO₆
• 分子量: 357.363
• InChiKey: LPHDEWSUQKMYMG-UHFFFAOYSA-N

物化性质

• 沸点：
  542.5±50.0 °C(Predicted)
• 密度：
  1.307±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  94.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-(2-hydroxy-2-ethoxyacetyl)-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one 在 三氟乙酸 作用下， 以134 mg (29%, trifluoroacetate)的产率得到8-(2-{3-[3-(4-fluoro-phenyl)-5-methyl-[1,2,4]triazol-1-yl]-1,1-dimethyl-propylamino}-1-hydroxy-ethyl)-6-hydroxy-4H-benzo[1,4]oxazin-3-one
  参考文献：
  名称：

  DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES

  摘要：

  本发明涉及除了一个或多个，更优选的是一个具有通用公式（1）的化合物，其中n、A、R1、R2和R3的含义如权利要求和描述中所述，至少还包含另一种活性成分2及其生产方法和作为药物的使用。

  公开号：

  US20090324510A1
• 作为产物：
  描述：

  6-(benzyloxy)-8-(2,2-dihydroxyacetyl)-2H-benzo[b][1,4]oxazin-3(4H)-one 、 乙醇 反应 2.0h， 生成 8-(2-hydroxy-2-ethoxyacetyl)-6-(phenylmethoxy)-4H-1,4-benzoxazin-3-one
  参考文献：
  名称：

  Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy

  摘要：

  Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection. The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects. Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h. In summary, the preclinical pro. le of compound (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety pro. le. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.087

文献信息

• [DE] NEUE LANG WIRKSAME BETA-2-AGONISTEN, UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS<br/>[FR] NOUVEAUX BETA-2 AGONISTES A EFFET PROLONGE ET LEUR UTILISATION COMME MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005070908A1

  公开（公告）日：2005-08-04

  Die vorliegende Erfindung betrifft Verbindungen der Formel (1), worin die Gruppen X, Ra, Rb, R1, R1', R2, R2', R2'', R2''', V und n die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, sowie deren Verwendung als Arzneimittel, insbesondere zur Behandlung von entzündlichen und obstruktiven Atemwegserkrankungen.

  本发明涉及式(1)的化合物，其中X、Ra、Rb、R1、R1'、R2、R2'、R2''、R2'''、V和n可以是权利要求和说明书中所指的含义，以及它们用作药物，尤其是用于治疗炎性和阻塞性呼吸道疾病。
• Long-acting betamimetics for the treatment of respiratory complaints
  申请人：Konetzki Ingo

  公开号：US20060189607A1

  公开（公告）日：2006-08-24

  The present invention relates to compounds of formula 1, wherein n, A, R 1 , R 2 and R 3 may have the meanings specified in the description and claims, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

  本发明涉及式1化合物，其中n、A、R1、R2和R3的含义如说明和权利要求所述，以及它们的制备过程和作为药物组合物，尤其是作为治疗呼吸道疾病的药物组合物的用途。
• New betamimetics for the treatment of respiratory complaints
  申请人：Bouyssou Thierry

  公开号：US20060063817A1

  公开（公告）日：2006-03-23

  The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R 1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

  本发明涉及公式1的化合物，其中n、m、B、X和R1的含义如权利要求和说明书中所给，以及它们的制备过程和作为药物组合物的用途，尤其是作为治疗呼吸系统疾病的药物组合物的用途。
• Medicament Combinations for the Treatment of Respiratory Diseases
  申请人：Konetzki Ingo

  公开号：US20070203125A1

  公开（公告）日：2007-08-30

  The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R 1 , X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  本发明涉及新的药物组合物，除了一个或多个，最好是1号通用公式中的一个化合物外，其中A、B、R1、X、n和m的含义如权利要求和说明书中所给，至少还包含另一种活性物质2，以及它们的制备方法和作为药物组合物的用途。
• New long acting beta-2-agonists and their use as medicaments
  申请人：Bouyssou Thierry

  公开号：US20050227975A1

  公开（公告）日：2005-10-13

  The present invention relates to compounds of formula 1 wherein the groups X, R a , R b , R 1 , R 1′ , R 2 , R 2′ , R 2″ , R 2′″ , V and n may have the meanings given in the claims and in the specification, and the use thereof as pharmaceutical compositions, particularly for the treatment of inflammatory and obstructive respiratory complaints.

  本发明涉及公式1的化合物，其中X、Ra、Rb、R1、R1′、R2、R2′、R2″、R2′″、V和n的含义如权利要求和说明书中所述，以及它们作为药物组合物的用途，特别是用于治疗炎性和阻塞性呼吸道疾病。